Reply - 28/02/18

| This study was supported by the BC Lung Association and the Canadian Respiratory Research Network. |
|
| Disclosure of potential conflict of interest: F. S. L. Filho received a grant from Research Project: IgG in COPD for other works. R. S. Schellenberg personally received fees for participating in review activities from DSMB - Boston Scientific - Green Cross for this work; personally received board membership from CSL Behring, Merck Canada, Novartis Canada, and AstraZeneca Canada for other works; and payment for lectures from Novartis Canada, Merck Canada, CSL Behring, and Meda Canada; his institution received grants from Octagam efficacy trial. D. D. Sin reports grants and personal fees from AstraZeneca and Boehringer Ingelheim; grants from Merck Frosst; and personal fees from Novartis, Regeneron, and Sanofi Aventis for other works. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 141 - N° 2
P. 831 - février 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
